Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
NCT ID: NCT04359706
Last Updated: 2022-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
34 participants
OBSERVATIONAL
2020-05-08
2020-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
NCT04365764
Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic
NCT06349707
Lung Bacteriobiota and Influenza Mortality
NCT04131296
Microecology and Host Immunity in Patients With Severe COVID-19 Infection
NCT05670275
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Respiratory and fecal microbiota (microbial and fungal) will be determined in COVID-19 patients on bronchoalveolar lavage and rectal swab.
Inflammatory biomarkers will also be measured in COVID-19 patients.
Characteristics of study patients will be collected at ICU admission and during ICU stay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Covid-19 group
Critically ill patients with SARS-CoV-2 infection
No interventions assigned to this group
control group
Historical critically ill patients with no SARS-CoV-2 infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For the Control Group:
* Historic cohort of non SARS -CoV2-infected adults admitted to the ICU (between March and October 2019),
* that was investigated for fecal microbiota in a previous study (control patients in a fecal microbiota study in patients included in the SEAT study).
Exclusion Criteria
* Lack of coverage Patients who received antibiotic therapy within 6 weeks prior to Covid-19 symptomatology,
* Pregnant women,
* Severe immunosuppression: Neutropenia \< 0.5 G/L, Chemotherapy \< 6 months, Bone marrow transplant recipients, HIV with CD4+ lymphocytes \< 0.4 G/L
* Impossible to perform bronchoalveolar lavage,
* Non-socially insured,
* Refusal to participate in the social study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saad Nseir, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Roger Salengro, CHU Lille
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A01042-37
Identifier Type: OTHER
Identifier Source: secondary_id
2020_28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.